The days following a serious injury can be a critical window for healthcare providers to safeguard a patient’s mental health alongside physical healing. A small study conducted by the University of Florida indicates that administering the antidepressant fluoxetine during recovery might lessen symptoms of post-traumatic stress disorder (PTSD).
Commonly known by its brand name Prozac, fluoxetine was given to patients after traumatic injuries in this study. Those who received the medication experienced a more notable reduction in PTSD symptoms over the following year compared to those who were given calcium as a control.
Traditionally, trauma care emphasizes immediate survival and physical recovery, addressing bleeding, repairing broken bones, preventing infection, and restoring mobility. However, the emotional toll often persists long after visible injuries have healed. Researchers estimate that nearly half of individuals with traumatic injuries see some decline in mental health afterward. While not everyone develops PTSD, ongoing fear, depression, sleep issues, pain, and intrusive memories can greatly complicate recovery.
PTSD can develop after experiencing or witnessing events involving serious injury, death, or threats, affecting relationships, work, sleep, and daily functioning. Symptoms may linger for months or years. Dr. Jennifer Hagen, an orthopedic surgeon at the University of Florida, and her team questioned whether waiting for PTSD symptoms to appear was the only option. They investigated if early medication intervention could reduce the development or severity of trauma-related symptoms.
Initially, the researchers tried a resilience-building, non-drug approach following injury, but results showed minimal improvement. They then collaborated with psychiatric specialists and decided to explore the use of fluoxetine, a widely prescribed antidepressant that influences serotonin signaling in the brain. Antidepressants like fluoxetine are used to treat depression and anxiety, and they are also common in PTSD management.
The study enrolled 68 patients who arrived at UF Health Shands Level I Trauma Center with serious injuries such as significant limb fractures or pelvic breaks. Participants were randomly assigned to two groups: one received fluoxetine for nine months, while the other was given calcium. Both groups were monitored for an additional three months.
By the six-month mark, only 35 participants remained in the study, and at the one-year follow-up, data from 29 participants were available. Results showed that those taking fluoxetine experienced a significant decrease in PTSD symptoms over the year, whereas symptoms in the calcium group showed little change. Additionally, individuals on fluoxetine reported lower levels of pain.
These findings suggest that fluoxetine might influence the trajectory of mental health recovery after trauma, rather than just treating symptoms after they arise. Interestingly, the study also observed reduced pain levels among those taking the medication.
However, the study had limitations. It was unblinded, meaning both patients and researchers knew who was receiving the drug, which could influence perceptions and reporting of symptoms, especially for subjective measures like pain and PTSD symptoms. The considerable participant drop-out rate further complicates the interpretation, as those who remained might differ in meaningful ways from those who left. The small sample size of 29 participants means the results are preliminary and need more rigorous testing.
The researchers also pointed out that stigma surrounding mental health treatments may hinder participation, as some individuals might avoid studies involving antidepressants due to concerns about being labeled with a psychiatric condition. To address this, they are now conducting a more rigorous, double-blind, placebo-controlled trial, where neither patients nor researchers know who receives the actual medication, providing a clearer picture of fluoxetine’s true effectiveness.
For now, these preliminary findings should be viewed as promising but not conclusive. Confirming the results in larger, controlled studies could eventually shift trauma care paradigms—beyond urgent physical repair, proactively safeguarding mental health might become a routine part of trauma recovery.














